Monoclonal antibodies set for a boom by 2019 due to favorable market conditions

15 September 2014
2019_biotech_test_vial_discovery_big

The monoclonal antibodies market for gastric and esophageal cancer is expected to double by 2019, according to a report by market research firm Reportstack. This is due to favorable market conditions due to US pricing structures and the anticipation that a number of drugs currently in late-stage development will be approved.

The monoclonal antibody market in gastric cancer will grow from $256 million in 2012 to $501 million by 2019 at a compound annual growth rate (CAGR) of 10%, while esophageal cancer monoclonal antibodies are expected to make $265 million by 2019, from $137 million in 2012, a CAGR of 9.9%.

Swiss drug major Roche's (ROG: SIX) Herceptin (trastuzumab) is currently the only monoclonal antibody available for gastric and esophageal cancer, as well as its indication for breast cancer, and gained approval from the US Food and Drug Administration for the two indications in 2010. Its patient is due to expire in the European Union in 2014 and in the US in 2019.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology